1. Home
  2. BFS vs NTLA Comparison

BFS vs NTLA Comparison

Compare BFS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BFS
  • NTLA
  • Stock Information
  • Founded
  • BFS 1993
  • NTLA 2014
  • Country
  • BFS United States
  • NTLA United States
  • Employees
  • BFS N/A
  • NTLA N/A
  • Industry
  • BFS Real Estate Investment Trusts
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • BFS Real Estate
  • NTLA Health Care
  • Exchange
  • BFS Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • BFS 873.4M
  • NTLA 1.0B
  • IPO Year
  • BFS 1993
  • NTLA 2016
  • Fundamental
  • Price
  • BFS $34.65
  • NTLA $6.53
  • Analyst Decision
  • BFS Strong Buy
  • NTLA Buy
  • Analyst Count
  • BFS 1
  • NTLA 18
  • Target Price
  • BFS $45.50
  • NTLA $39.44
  • AVG Volume (30 Days)
  • BFS 51.0K
  • NTLA 3.4M
  • Earning Date
  • BFS 05-01-2025
  • NTLA 05-08-2025
  • Dividend Yield
  • BFS 6.67%
  • NTLA N/A
  • EPS Growth
  • BFS N/A
  • NTLA N/A
  • EPS
  • BFS 1.63
  • NTLA N/A
  • Revenue
  • BFS $268,847,000.00
  • NTLA $57,877,000.00
  • Revenue This Year
  • BFS $7.78
  • NTLA N/A
  • Revenue Next Year
  • BFS $6.78
  • NTLA N/A
  • P/E Ratio
  • BFS $21.70
  • NTLA N/A
  • Revenue Growth
  • BFS 4.53
  • NTLA 59.55
  • 52 Week Low
  • BFS $34.98
  • NTLA $6.50
  • 52 Week High
  • BFS $42.39
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • BFS 43.17
  • NTLA 32.93
  • Support Level
  • BFS $35.65
  • NTLA $6.50
  • Resistance Level
  • BFS $36.51
  • NTLA $7.59
  • Average True Range (ATR)
  • BFS 0.56
  • NTLA 0.56
  • MACD
  • BFS 0.03
  • NTLA -0.17
  • Stochastic Oscillator
  • BFS 35.07
  • NTLA 11.28

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates, and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: